$Flexion Therapeutics(FLXN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-049605 Size: 7 KB 网页链接
$Flexion Therapeutics(FLXN)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-21-000785 Act: 34 Size: 9 MB 网页链接
$Flexion Therapeutics(FLXN)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-21-000784 Act: 34 Size: 856 KB 网页链接
$Flexion Therapeutics(FLXN)$ 内部交易: 2021-07-19,General Counsel,Levine Mark S. ,卖出,3945普通股, $6.45
$Flexion Therapeutics(FLXN)$ 内部交易: 2021-07-19,Chief Business Officer,Muzikant Adam ,卖出,1870普通股, $6.45
$Flexion Therapeutics(FLXN)$ 内部交易: 2021-07-19,Chief Regulatory Officer,Wentworth Kerry ,卖出,3944普通股, $6.45
$Flexion Therapeutics(FLXN)$ 内部交易: 2021-07-19,Chief Strategy Officer,Willwerth Christina ,卖出,3945普通股, $6.45
$Flexion Therapeutics(FLXN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-047503 Size: 5 KB 网页链接
$Flexion Therapeutics(FLXN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-047504 Size: 5 KB 网页链接
$Flexion Therapeutics(FLXN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-21-047506 Size: 5 KB 网页链接